Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business. Read why I think HIMS stock is ...

Much of the excitement over Hims & Hers has been connected to the company's sales of compounded versions of GLP-1 inhibitor semaglutide. Novo Nordisk markets semaglutide as a treatment for type 2 ...

An ad for compounded versions of weight-loss drug semaglutide by telehealth company Hims & Hers has attracted the ire of a pharmaceutical trade organisation that calls the campaign "nothing short ...

The bank assigned a price target of $22 for Hims & Hers, implying a downside of around 25%. To demonstrate the value of its loss, compounded semaglutide drug sales brought in $225 million in ...

Hims & Hers had previously offered compounded versions of semaglutide -- the GLP-1 drug marketed as Ozempic and Wegovy -- which it and other compounding pharmacies were allowed to do legally ...

In May, Hims & Hers started prescribing compounded semaglutide, the active ingredient in Novo Nordisk's GLP-1 weight loss medications Ozempic and Wegovy. The offering was immensely popular and ...

Their tight supply had allowed Hims & Hers and others to sell cheaper versions of Novo's semaglutide. Hims & Hers said in February it cannot guarantee to continue to sell compounded semaglutide ...

Hims & Hers Health stock plummeted after an FDA decision that prevents the company from selling compounded semaglutide. The company still expects to deliver strong revenue growth, though ...